ICON has climbed recently yet still carries a share price history that includes a sizeable multi year decline, which puts fresh focus on whether the current US$185.27 level is properly grounded in its underlying cash flows. With investors weighing upbeat headlines against a mixed return profile, the question is how well the cash the business can generate lines up with what the market is now paying for the stock.
The stock's next move may depend on whether ICON's current market price lines up with what its cash flows suggest as an intrinsic value over time.
If you are weighing ICON against other opportunities built around cash generation and valuation resets, it can help to line it up beside 29 high quality undervalued stocks.
The Discounted Cash Flow (DCF) model here focuses on the cash ICON can return to shareholders over time. Over the last twelve months the group produced about $1.02b of free cash flow, and the projections used in the model assume this pool of cash continues to grow rather than contract.
Analysts feeding into the DCF expect ICON’s free cash flow to rise over the next decade at moderating rates, which looks more like a mature compounding profile than a high risk spike. On that set of assumptions, and after discounting those future dollars back to today, the model suggests an intrinsic value that is meaningfully above the current share price of $185.27. RBC’s recent focus on a strong order backlog and 2027 book to bill strength helps explain why the cash flow outlook used in the model remains constructive even as questions around revenue trends and margins keep the market more cautious. Find out what ICON could be worth using our Discounted Cash Flow (DCF) estimate.
Narratives for ICON pick up where the valuation puzzle leaves off, spelling out which paths for ICON's growth, profitability and earnings would need to play out for the share price to sit meaningfully above or below where it trades today on Simply Wall St's Community page. Instead of a single DCF output or valuation ratio, you see the underlying future those figures rely on, so you can watch over time whether that story still lines up.
ICON draws two very different reads from the community, with one group seeing meaningful upside and another treating it as closer to fully priced.
Bull case: 12% undervalued
"The main thing that has to go right is that ICON converts strong bookings and RFP flow in areas like oncology, cardiometabolic, and biotech into profitable revenue..."
Discover why this Narrative puts ICON at 12% undervalued.
Bear case: 16% overvalued
"Management now guides to an approximate 2% organic decline in direct fee revenue for 2026 while pass through revenue is expected to be broadly flat..."
Explore why this Narrative puts ICON at 16% overvalued.
ICON's pricing story only goes so far without understanding the areas where automated checks are flashing caution, and those potential pressure points sit in a separate set of findings. Take a closer look at 2 warning signs before settling on a valuation.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com